Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics

• Váldodahkkit: Bérénice Charrez (Dahkki), Verena Charwat (Dahkki), Brian A. Siemons (Dahkki), Ishan Goswami (Dahkki), Courtney Sakolish (Dahkki), Yu-Syuan Luo (Dahkki), Henrik Finsberg (Dahkki), Andrew G. Edwards (Dahkki), Evan W. Miller (Dahkki), Ivan Rusyn (Dahkki), Kevin E. Healy (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Despite global efforts, it took 7 months between the proclamation of global SARS-CoV-2 pandemic and the first FDA-approved treatment for COVID-19. During this timeframe, clinicians focused their efforts on repurposing drugs, such as hydroxychloroquine (HCQ) or azithromycin (AZM) to treat hospitalize...